Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Operating Grant - PA: Genetics (Bridge Funding: Research Priorities)

Université Laval

$100,000.00

Correction with the Prime editing technology of point mutations responsible for Duchenne Muscular Dystrophy.

EF 2022-23

Résumé
Duchenne Muscular Dystrophy (DMD) is due to various mutations in a large gene called DMD, which contains thousands of nucleotides coding for a protein called dystrophin, a protein normally located under the membrane of the muscle fibers. There are different types of DMD gene mutations: 1) deletions of a one or several groups of nucleotides (called exons) and 2) modifications of only one or a few nucleotides (called point mutations). In both cases these mutations lead to the presence of a stop signal, which induces the premature termination of the dystrophin protein synthesis by muscle fibers. The absence of a complete dystrophin protein under the membrane of the muscle fibers leads to damages of muscle fibers during contraction inducing progressive muscle weakness. We propose to use a new gene editing technique called "CRISPR-Cas9 Prime editing" to correct the mutations and restore the presence of the dystrophin in DMD patient small muscle fibers (myotubes) in culture and in vivo in 5 DMD mouse models. Prime editing permits to induce precise modifications of one or a few nucleotides. So far, we have been able to modify nucleotides present in 9 different DMD point mutations in Canadian population. We have shown that this led to the presence of the dystrophin in myotubes. In the present project, we will use two recent Prime editing improvements, which may permit to increase gene editing by up to 4 folds. We will also do experiments to demonstrate that the dystrophin expression is restored in the muscles of 5 DMD mouse models. We will test two in vivo delivery methods: adeno associated virus and virus like particles. We will also do experiments to demonstrate that the Prime editing technique may also be used to restore dystrophin expression when one or several DMD exons are deleted. We hope that these experiments will permit to initiate a discussion with Health Canada to obtain the permission for a Phase I clinical trial of this new therapeutic approach for DMD.
Programme
Operating Grant - PA: Genetics (Bridge Funding: Research Priorities)
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
472649
Name
Tremblay Jacques P
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Molecular & Cellular Neurosciences - B
Projecttitle
Correction with the Prime editing technology of point mutations responsible for Duchenne Muscular Dystrophy.
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant - PA: Genetics (Bridge Funding: Research Priorities)
Keyworddelim
Adeno Associated Virus; Crispr; Duchenne Muscular Dystrophy; Genome Editing; Hereditary Disease; Nucleotide Editing; Prime Editing
Abstract
Duchenne Muscular Dystrophy (DMD) is due to various mutations in a large gene called DMD, which contains thousands of nucleotides coding for a protein called dystrophin, a protein normally located under the membrane of the muscle fibers. There are different types of DMD gene mutations: 1) deletions of a one or several groups of nucleotides (called exons) and 2) modifications of only one or a few nucleotides (called point mutations). In both cases these mutations lead to the presence of a stop signal, which induces the premature termination of the dystrophin protein synthesis by muscle fibers. The absence of a complete dystrophin protein under the membrane of the muscle fibers leads to damages of muscle fibers during contraction inducing progressive muscle weakness. We propose to use a new gene editing technique called "CRISPR-Cas9 Prime editing" to correct the mutations and restore the presence of the dystrophin in DMD patient small muscle fibers (myotubes) in culture and in vivo in 5 DMD mouse models. Prime editing permits to induce precise modifications of one or a few nucleotides. So far, we have been able to modify nucleotides present in 9 different DMD point mutations in Canadian population. We have shown that this led to the presence of the dystrophin in myotubes. In the present project, we will use two recent Prime editing improvements, which may permit to increase gene editing by up to 4 folds. We will also do experiments to demonstrate that the dystrophin expression is restored in the muscles of 5 DMD mouse models. We will test two in vivo delivery methods: adeno associated virus and virus like particles. We will also do experiments to demonstrate that the Prime editing technique may also be used to restore dystrophin expression when one or several DMD exons are deleted. We hope that these experiments will permit to initiate a discussion with Health Canada to obtain the permission for a Phase I clinical trial of this new therapeutic approach for DMD.
Competitiondate
202209
Approvedterm2
1 yr 0 mth
Pinamesdelim
Tremblay, Jacques P
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~